Hardman & Co Research Report: Pipeline progress

RNS Number : 7157M

Redx Pharma plc

22 January 2016

 

Hardman & Co issues research report on Redx Pharma

Pipeline progress - Porcupine inhibitor: Redx is a drug discovery company, offering investors access to a new R&D model; not without risk, but one that is mitigated by the breadth, depth and focus given to its pipeline. It has developed a broad early stage preclinical pipeline focusing on cancer, immunology and anti-infectives, particularly microbial resistance - all considered "hot" areas of scientific and commercial interest - validated to an extent by six partnerships. Its Porcupine inhibitor has started IND-enabling studies with a view to commencing clinical trials in the next 12 months is another example of the rapid progress of its discovery engine, and is likely to command plenty of external interest.

Please click here for the full report:

http://www.hardmanandco.com/system/files/research_papers/Redx Pharma.pdf

To contact us:    Hardman & Co 11/12 Tokenhouse Yard  London EC2R 7AS

Contact: Dr Martin Hall [e-mail]  Telephone: [phone] Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

END

 

 

NRAAKBDKCBKKODB